Northwest Biotherapeutics reported $30.61M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Agenus USD 186.46M 40.34M Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Celldex Therapeutics USD 511.25M 71.73M Mar/2026
Eisai JPY 1.45T 37.11B Mar/2026
Infinity Pharmaceuticals USD 21.23M 8.72M Jun/2023
Merck USD 128.68B 8.18B Mar/2026
Northwest Biotherapeutics USD 30.61M 1.06M Sep/2025
Pfizer USD 207.62B 542M Mar/2026
Plus Therapeutics USD 19.92M 3.59M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025